Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Halden

65 clinical trials in Halden, Norway. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Halden at a glance
65
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

65 trials in Halden

Open in trial search

Safety and Pharmacodynamics of RBD4059 and Apixaban in Patients with Non‑Valvular Atrial Fibrillation: A Randomized Active‑Controlled Study

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Ribocure Pharmaceuticals AB

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A study to evaluate the effectiveness of tenecteplase in patients with acute ischemic stroke who are more than 4.5 hours after their last known well time.

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Tenecteplase
  • Sponsor:Boehringer Ingelheim International GmbH

Study of Izalontamab Brengitecan Compared to Platinum-Based Chemotherapy for Patients with Metastatic Urothelial Cancer After Immunotherapy

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Major depression+1

Recruiting

A study on ketamine maintenance treatment for patients with treatment-resistant major depression disorder

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Ketamine Hydrochloride
  • Sponsor:Ostfold Hospital Trust

A Follow-up Study of Mezagitamab in Adults with Chronic Primary Immune Thrombocytopenia to Evaluate Long-term Safety and Effectiveness

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Mezagitamab
  • Sponsor:Takeda Development Center Americas Inc.
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Region Midtjylland

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.